Your browser is no longer supported. Please, upgrade your browser.
Settings
ITCI Intra-Cellular Therapies, Inc. daily Stock Chart
ITCI [NASD]
Intra-Cellular Therapies, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own0.80% Shs Outstand58.06M Perf Week3.54%
Market Cap577.12M Forward P/E- EPS next Y-3.56 Insider Trans189.46% Shs Float48.80M Perf Month10.57%
Income-154.50M PEG- EPS next Q-0.81 Inst Own78.70% Short Float14.51% Perf Quarter-20.54%
Sales- P/S- EPS this Y-32.40% Inst Trans-0.25% Short Ratio5.70 Perf Half Y-25.93%
Book/sh4.66 P/B2.13 EPS next Y-10.90% ROA-44.30% Target Price25.89 Perf Year-53.51%
Cash/sh4.91 P/C2.02 EPS next 5Y- ROE-50.80% 52W Range7.41 - 23.62 Perf YTD-12.73%
Dividend- P/FCF- EPS past 5Y-12.70% ROI- 52W High-57.92% Beta1.22
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low34.14% ATR0.67
Employees73 Current Ratio8.90 Sales Q/Q- Oper. Margin- RSI (14)53.46 Volatility11.74% 6.46%
OptionableYes Debt/Eq0.00 EPS Q/Q0.60% Profit Margin- Rel Volume0.89 Prev Close10.46
ShortableYes LT Debt/Eq0.00 EarningsAug 08 Payout- Avg Volume1.24M Price9.94
Recom1.40 SMA208.50% SMA502.86% SMA200-17.76% Volume1,102,298 Change-4.97%
Aug-12-19Initiated Jefferies Buy $16
Feb-26-18Initiated JP Morgan Overweight
Feb-08-18Initiated RBC Capital Mkts Outperform $33
Dec-15-17Initiated Canaccord Genuity Buy $31
Nov-08-17Upgrade SunTrust Hold → Buy
Sep-07-17Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17Downgrade Leerink Partners Outperform → Mkt Perform
May-02-17Downgrade Ladenburg Thalmann Buy → Neutral
May-01-17Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16Initiated Cantor Fitzgerald Overweight
Sep-29-16Reiterated RBC Capital Mkts Outperform $74 → $49
Sep-29-16Downgrade SunTrust Buy → Neutral
Sep-29-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-02-16Initiated Piper Jaffray Overweight
Nov-06-15Reiterated RBC Capital Mkts Outperform $62 → $74
Sep-17-15Reiterated RBC Capital Mkts Outperform $42 → $62
Sep-17-15Reiterated Guggenheim Buy $36 → $95
Sep-10-19 11:33AM  FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug Benzinga
07:30AM  Intra-Cellular Therapies Provides Lumateperone Regulatory Update GlobeNewswire
Aug-28-19 08:48AM  How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay? Simply Wall St.
Aug-19-19 06:00AM  5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool
Aug-07-19 08:00AM  Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 08:00AM  Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Aug-05-19 07:30AM  Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA GlobeNewswire +8.46%
Jul-24-19 10:58AM  Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks
Jul-23-19 07:30PM  Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia GlobeNewswire -31.64%
04:30PM  Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today Motley Fool
07:11AM  Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated? Simply Wall St.
Jul-09-19 11:10AM  A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019 Benzinga
09:49AM  Company News For Jul 9, 2019 Zacks
09:45AM  Intra-Cellular Therapies' Candidate Fails in Phase III Study Zacks
Jul-08-19 04:51PM  Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today Motley Fool -13.08%
01:50PM  A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga
11:34AM  Why Intra-Cellular Therapies Is Tanking Today Motley Fool
08:58AM  Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results MarketWatch
08:52AM  Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression Benzinga
07:54AM  UPDATE 1-Intra-Cellular drug fails one of two bipolar depression studies; shares fall Reuters
07:18AM  Intra-Cellular drug fails one of two bipolar depression studies Reuters
07:14AM  Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression MarketWatch
07:00AM  Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression GlobeNewswire
Jul-06-19 02:45PM  The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings Benzinga
Jul-05-19 02:49PM  Intra-Cellular Shares May Double on Bipolar Depression Data Bloomberg
08:43AM  Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? Zacks
Jul-02-19 08:00AM  Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer GlobeNewswire
Jul-01-19 12:55PM  7 Stocks on Sale the Insiders Are Buying InvestorPlace +8.09%
Jun-26-19 02:06PM  Here is What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI) Insider Monkey
Jun-19-19 08:00AM  Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference GlobeNewswire
Jun-17-19 10:11AM  Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility Simply Wall St. +13.11%
08:39AM  Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options Zacks
Jun-13-19 08:55AM  Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults GlobeNewswire +8.63%
May-30-19 08:00AM  Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-20-19 08:41AM  2 Biotech Names See Directors Direct Cash to Their Shares TheStreet.com
May-17-19 03:14AM  Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 08:00AM  Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-15-19 08:00AM  Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting GlobeNewswire
May-10-19 01:15PM  Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57% Simply Wall St.
May-08-19 04:06PM  Heres What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI) Insider Monkey
01:26PM  Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript Motley Fool
07:42AM  Intra-Cellular: 1Q Earnings Snapshot Associated Press
07:30AM  Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-02-19 08:00AM  Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast GlobeNewswire
Apr-29-19 08:56AM  Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? Zacks
Apr-16-19 08:00AM  Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard GlobeNewswire
Apr-15-19 07:00AM  Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society GlobeNewswire
Apr-02-19 11:40AM  Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61% Simply Wall St. +7.91%
Mar-26-19 07:00AM  Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs GlobeNewswire
Mar-05-19 08:00AM  Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-04-19 06:01PM  Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 11:30AM  Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.66%
07:30AM  Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 08:00AM  Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-20-19 08:00AM  Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast GlobeNewswire
Feb-19-19 07:40AM  Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
Jan-23-19 12:09PM  Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Simply Wall St.
Jan-03-19 11:20AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI ACCESSWIRE
08:00AM  Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-18 02:26PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI GlobeNewswire
Dec-28-18 12:10AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI ACCESSWIRE
Dec-19-18 06:21AM  Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy? Insider Monkey -5.65%
Dec-18-18 02:01PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI PR Newswire
01:00PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI) GlobeNewswire
08:52AM  Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial MarketWatch
08:30AM  Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease GlobeNewswire
Dec-17-18 01:13PM  How Should Investors React To Intra-Cellular Therapies, Inc.s (NASDAQ:ITCI) CEO Pay? Simply Wall St. -5.02%
Dec-11-18 05:30PM  Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire
07:00AM  Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia GlobeNewswire
Nov-20-18 07:32AM  Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 02:53PM  Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta? Simply Wall St.
10:37AM  Intra-Cellular: 3Q Earnings Snapshot Associated Press
07:00AM  Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 08:00AM  Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire +9.66%
Oct-25-18 07:20AM  Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group Discovering Underlying Factors of Influence GlobeNewswire +6.96%
Oct-23-18 07:00AM  Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinsons Disease GlobeNewswire
Oct-17-18 08:00AM  Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinsons Disease at 2018 American Neurological Association Annual Meeting GlobeNewswire
Oct-16-18 08:00AM  Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer GlobeNewswire +5.49%
Oct-15-18 08:35AM  Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-18 09:00AM  Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock Zacks -5.10%
Sep-28-18 07:00AM  Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia GlobeNewswire
Sep-26-18 08:00AM  Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-25-18 07:00AM  Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs GlobeNewswire +6.31%
Sep-18-18 08:54AM  Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company? Simply Wall St.
Sep-05-18 07:55AM  New Research: Key Drivers of Growth for Intra-Cellular Therapies, The, Bassett Furniture Industries, NVE, Equity Bancshares, and Cable One Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-20-18 08:00AM  Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs GlobeNewswire
Aug-15-18 07:35AM  Detailed Research: Economic Perspectives on Neos Therapeutics, Federated National Holding, FutureFuel, Golden Entertainment, Intra-Cellular Therapies, and HTG Molecular Diagnostics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-06-18 03:19AM  Edited Transcript of ITCI earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:19AM  Intra-Cellular: 2Q Earnings Snapshot Associated Press +5.61%
07:09AM  Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-18 08:00AM  Intra-Cellular Therapies to Host Second Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire
Jul-25-18 09:15AM  Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc. Motley Fool
Jul-23-18 07:00AM  Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure GlobeNewswire
Jul-21-18 08:44AM  Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga
Jul-16-18 07:10AM  Complimentary Technical Snapshots on Intercept Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 07:00AM  Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia GlobeNewswire +5.36%
May-31-18 08:00AM  Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alafi Christopher DDirectorSep 10Buy10.26485,0004,974,6784,673,270Sep 11 04:30 PM
Alafi Christopher DDirectorAug 30Buy8.52125,0001,065,2134,188,270Sep 04 06:24 PM
Alafi Christopher DDirectorJun 12Buy11.73170,0001,993,793170,000Jun 14 05:23 PM
MARCUS JOEL SDirectorMay 29Option Exercise12.4520,000249,00041,671May 31 04:35 PM
Alafi Christopher DDirectorMay 14Buy12.56100,0001,256,3504,053,270May 15 06:03 PM
Hineline Lawrence J.SVP of Finance CFOFeb 27Option Exercise2.7410,40028,49626,232Mar 01 07:41 PM
Hineline Lawrence J.SVP of Finance CFOFeb 27Sale15.001,00015,00025,232Mar 01 07:41 PM
Vanover Kimberly E.SVP, Early Stage Clinical Dev.Jan 07Sale12.295927,27627,068Jan 08 09:19 PM
Hineline Lawrence J.SVP of Finance CFOJan 07Sale12.423,10838,60117,032Jan 08 09:21 PM
Halstead MichaelEVP and General CounselJan 07Sale12.423,10838,601191Jan 08 09:24 PM
Mates SharonChairman, President & CEOJan 07Sale12.436,60482,0881,138,707Jan 08 09:28 PM
Mates SharonChairman, President & CEOJan 04Sale11.4545,598522,2221,145,311Jan 08 09:28 PM
Halstead MichaelEVP and General CounselJan 04Sale11.4621,458245,8173,299Jan 08 09:24 PM
Hineline Lawrence J.SVP of Finance CFOJan 04Sale11.4521,458245,78220,140Jan 08 09:21 PM
Vanover Kimberly E.SVP, Early Stage Clinical Dev.Jan 04Sale11.479,564109,70427,660Jan 08 09:19 PM
Davis Robert ESVP, Chief Scientific OfficerJan 04Sale11.469,564109,63043,989Jan 08 09:16 PM
Mates SharonChairman, President & CEOJan 02Sale11.0917,478193,8311,138,707Jan 03 09:02 PM
Halstead MichaelEVP and General CounselJan 02Sale11.097,80786,580191Jan 03 08:58 PM
Vanover Kimberly E.SVP, Early Stage Clinical Dev.Jan 02Sale11.104,83453,65716,861Jan 03 08:46 PM
Davis Robert ESVP, Chief Scientific OfficerJan 02Sale11.114,83453,70634,744Jan 03 08:42 PM
Hineline Lawrence J.SVP of Finance CFOJan 02Sale11.097,80786,58017,032Jan 03 08:23 PM
Mates SharonChairman, President & CEODec 10Option Exercise1.5050,00075,0001,138,707Dec 11 05:55 PM
Davis Robert ESVP, Chief Scientific OfficerDec 06Sale13.5389912,16330,256Dec 07 04:44 PM
MARCUS JOEL SDirectorNov 12Sale17.947,000125,58078,742Nov 13 05:34 PM
MARCUS JOEL SDirectorNov 09Sale18.2425,000456,00085,742Nov 13 05:34 PM
LERNER RICHARD ADirectorOct 22Option Exercise1.5012,50018,75066,911Oct 24 04:33 PM